Debut, a biotech beauty company, has launched DermCeutical EDL™, a topical ingredient it claims delivers professional-grade skin tightening results. Developed using AI, skin genomics and biotechnology, the ingredient activates cellular pathways typically targeted by in-office treatments. In a 12-week clinical study, DermCeutical EDL™ showed 100% fine-line improvement rate and 73% improvement in skin sagging compared to placebo. The ingredient increased elastin production six-fold and rejuvenated aged cells by 31%, whilst improving texture, luminosity and fine lines. The bioactive works by activating dermal fibroblasts to boost elastin production whilst reducing cellular stress. CEO Joshua Britton said the technology allows consumers to achieve visible results at home without expensive in-office treatments. DermCeutical EDL™ joins Debut's growing portfolio of biotech skincare actives.

Debut appoints Derek Wanner as Chief commercial officer to accelerate biotech-powered beauty innovation. Beauty biotech specialist Debut has announced the appointment of Derek Wanner as chief commercial officer (CCO). Debut Beauty biotech specialist Debut has announced the appointment of Derek Wanner as chief commercial officer (CCO). Wanner joins Debut from Mana Products, a global manufacturer of beauty formulations, where he held senior commercial leadership roles and helped scale innovation across the global beauty industry. In his new role, Wanner will lead the growth of Debut's formulation business, expand strategic partnerships and collaborate with industry-leading beauty brands to bring cutting-edge, science-backed products to market faster. "Derek brings a rare combination of commercial rigor, formulation expertise, and deep industry relationships," said Joshua Britton, Ph.D., founder and CEO of Debut. "As demand accelerates for high-performance, clinically proven products, his leadership will be instrumental in scaling our formulation business and helping partners unlock the full power of biotechnology." Prior to Debut, Wanner served as Chief Growth Officer at Mana Products, where he helped propel some of the world's most influential beauty brands by expanding product development capabilities and supporting the growth of a diverse global portfolio. That experience now positions him to further Debut's mission of leveraging biotechnology as a competitive advantage across the beauty ecosystem. "What drew me to Debut is its ability to pair world-class biotechnology with a clear path to commercialization," said Wanner. "Debut's science-first approach represents a fundamental shift in how beauty formulations are created - from discovering novel, high-performing ingredients to enabling real personalization powered by AI and genomics. I'm excited to help scale these innovations and shape the future of beauty." Wanner's appointment comes as Debut builds on strong market momentum, expands its global commercial and biomanufacturing footprint, and deepens collaborations across the beauty industry.